Journal: bioRxiv

Article Title: Cardiovascular Disease-Associated Non-Coding Variants Disrupt GATA4-DNA Binding and Regulatory Functions

doi: 10.1101/2024.09.19.613959

Figure Lengend Snippet: Expression and purification of GATA4 ZF. A) SDS-PAGE (left) and western blot (right) of GATA4 ZF (18.8 kDa). Abbreviations: wash fractions (W), eluted fractions (E), concentrated fractions (C), un-induced protein sample (U), IPTG-induced protein sample (I), supernatant fraction (S), and pellet fraction (P). B) Western Blot of full-length GATA4 expressed in HeLA cells (48.6 kDa).

Article Snippet: HeLa Cervical Adenocarcinoma Human (HeLa) cells (ATCC–CCL-2) were grown in Eagle’s Minimum Essential Medium (EMEM) (ATCC - 30-2003) with 10% Fetal Bovine Serum (FBS) at 37 °C and 5% CO 2 .

Techniques: Expressing, Purification, SDS Page, Western Blot

Journal: bioRxiv

Article Title: Cardiovascular Disease-Associated Non-Coding Variants Disrupt GATA4-DNA Binding and Regulatory Functions

doi: 10.1101/2024.09.19.613959

Figure Lengend Snippet: CVD-associated SNPs alter gene expression and are in eQTL in cardiac tissue. A) Relative luciferase activity in HeLa cells transfected with reporter plasmids containing reference (blue with black circles) and alternate (orange with black squares) of variants rs1506537, rs56992000, rs2941506, and rs2301249. B) Cardiac tissue eQTL analysis of MRPL33 , TOP2B , PGAP3 , and CSK expressed in heart atrial appendage or left ventricle when rs1506537, rs56992000, rs2941506, and rs2301249 occur, respectively. C) University of California Santa Cruz (UCSC) Genome Browser tracks of variants rs2941506 and rs56992000 near TAD boundaries and regulatory elements.

Article Snippet: HeLa Cervical Adenocarcinoma Human (HeLa) cells (ATCC–CCL-2) were grown in Eagle’s Minimum Essential Medium (EMEM) (ATCC - 30-2003) with 10% Fetal Bovine Serum (FBS) at 37 °C and 5% CO 2 .

Techniques: Gene Expression, Luciferase, Activity Assay, Transfection

Journal: PLoS ONE

Article Title: Targeting Human Telomeric G-Quadruplex DNA and Inhibition of Telomerase Activity With [(dmb) 2 Ru(obip)Ru(dmb) 2 ] 4+

doi: 10.1371/journal.pone.0084419

Figure Lengend Snippet: TRAP Assay with Hela cells at gradient concentrations of [(dmb) 2 Ru(obip)Ru(dmb) 2 ] 4+ for 24 h shown in (A), quantitative analysis of the telomerase inhibition by ELISA shown in (B). PC means positive control with HEK293 provided by the kit, NC means the negative control obtained by heating Hela cell protein for 10 min at 85 °C. Hela means Hela cells untreated with [(dmb) 2 Ru(obip)Ru(dmb) 2 ] 4+ . 24 h, 48 h, 72 h means Hela cells respectively treated with the complex at MTT IC 50 = 120 nM for 24 h, 48 h and 72 h. Data were represented as mean +/- S.E.M. * means significant difference by GraphPad Prism5 One way ANOVA (Tukey's Multiple Comparison Test).

Article Snippet: In our experiment, we used two cancer cell lines of human cervical cancer Hela cells (RR-B51S, ATCC# PTA-5258) and chronic myelogenous leukemia cell line of K-562 (ATCC# CCL-243).

Techniques: TRAP Assay, Inhibition, Enzyme-linked Immunosorbent Assay, Positive Control, Negative Control, Comparison

Journal: PLoS ONE

Article Title: Targeting Human Telomeric G-Quadruplex DNA and Inhibition of Telomerase Activity With [(dmb) 2 Ru(obip)Ru(dmb) 2 ] 4+

doi: 10.1371/journal.pone.0084419

Figure Lengend Snippet: MTT assay was performed on human normal fibroblast cells treated with [(dmb) 2 Ru(obip)Ru(dmb) 2 ] 4 A), human cervical cancer Hela cells treated with [(dmb) 2 Ru(obip)Ru(dmb) 2 ] 4+ at gradient concentrations B), Hela cells treated with a clinical chemotherapeutic cisplatin C), K562 cells treated with [(dmb) 2 Ru(obip)Ru(dmb) 2 ] 4 D) and K562 cells treated with cisplatin respectively at gradient concentrations. The inhibition ratio was collected as the average of triplicate wells relative to that of the untreated wells. Result shown here was the representative one among three independent experiments. Data were presented as mean +/- S.E.M.* means P < 0.05, ** means P < 0.005, *** means P < 0.0001 significant difference was observed by GraphPad Prism5 Two-way RM ANOVA (Bonferroni posttests).

Article Snippet: In our experiment, we used two cancer cell lines of human cervical cancer Hela cells (RR-B51S, ATCC# PTA-5258) and chronic myelogenous leukemia cell line of K-562 (ATCC# CCL-243).

Techniques: MTT Assay, Inhibition

Journal: PLoS ONE

Article Title: Targeting Human Telomeric G-Quadruplex DNA and Inhibition of Telomerase Activity With [(dmb) 2 Ru(obip)Ru(dmb) 2 ] 4+

doi: 10.1371/journal.pone.0084419

Figure Lengend Snippet: A) The representative green fluorescence images taken under microscope after treatment with [(dmb) 2 Ru(obip)Ru(dmb) 2 ] 4+ at MTT IC 50 = 120 nM at different time points, B) the percentage of green fluorescence positive cells after [(dmb) 2 Ru(obip)Ru(dmb) 2 ] 4+ treatment in comparison with both the negative and positive controls. NC means the untreated Hela cells used as the negative control, PC means Hela cells treated with DNase I recombinant (3000U/ml-3U/ml in 50 mM Tris-HCl, PH 7.5, 1 mg/ml BSA) for 10 min at 15-25 °C used as the positive control. 24 h, 48 h and 72 h mean Hela cells treated with [(dmb) 2 Ru(obip)Ru(dmb) 2 ] 4+ for 24 h, 48 h and 72 h respectively before labelling. Scale bar 25 um. Data were presented as mean +/- S.E.M. * means significant difference was observed by GraphPad Prism5 One way ANOVA (Tukey's Multiple Comparison Test).

Article Snippet: In our experiment, we used two cancer cell lines of human cervical cancer Hela cells (RR-B51S, ATCC# PTA-5258) and chronic myelogenous leukemia cell line of K-562 (ATCC# CCL-243).

Techniques: Fluorescence, Microscopy, Comparison, Negative Control, Recombinant, Positive Control